Bringing Blood-Based Molecular Testing to the Clinic.
In cancer, plasma-derived cell-free DNA can be used for detection of oncogenic aberrations relevant for treatment selection. A cell-free DNA-based test for EGFR mutations has been approved as an alternative to tumor tissue analysis in lung cancer. Testing for other aberrations, including copy number alterations, continues to be investigated. Clin Cancer Res; 22(22); 5400-2. ©2016 AACRSee related article by Chicard et al., p. 5564.
Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
Filip
F
Janku
Center for Personalized Cancer Therapy, Moores Cancer Center, The University of California San Diego, La Jolla, California. rkurzrock@ucsd.edu.
Razelle
R
Kurzrock
D014408:Biomarkers, Tumor / Q000097:blood; D056915:DNA Copy Number Variations / Q000235:genetics; D004273:DNA, Neoplasm / Q000097:blood*; D066246:ErbB Receptors / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000235:genetics*; D009154:Mutation / Q000235:genetics
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D066246:ErbB Receptors